NRC HEALTH (NRC)

Nasdaq Biotechnology Biotech R&D SIC: 8731
D
Pipeline Grade

Financial Position (from SEC Filings)

$2.6M
Cash & Equivalents
$7.2M
Quarterly Burn Rate
$488M
Market Cap

Estimated from most recent SEC quarterly filing. View SEC filings

Drug Pipeline (0 Assets)

No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.

Upcoming Catalysts

DateEventDrug
2026-11-01 Phase2 Readout
2027-04-01 Phase2 Readout
2027-06-28 Phase3 Readout

Active Clinical Trials (14)

NCT #TitlePhaseStatusEnrollment
NCT06020677 Latinx Children and Surgery OTHER Recruiting 120
NCT06747871 Opioids, Low Nicotine Cigarettes, and Chronic Pain OTHER Recruiting 60
NCT06791122 A Prospective Cohort Study to Assess Clinical Effectiveness of an Investigational Digital Therapeutic (CT-155) in Patien... OTHER Active Not Recruiting 262
NCT07211035 Effect of the Amplifi™ Vein Dilation System on Outflow Vein Dilation and AV Fistula Maturation (AMPLIFI-1) OTHER Recruiting 160
NCT02993523 A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Mye... PHASE3 Active Not Recruiting 443
NCT07140913 A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Featur... PHASE3 Recruiting 424
NCT05304767 An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Control... PHASE3 Recruiting 280
NCT06929273 A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3) PHASE3 Recruiting 450
NCT05616650 Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor PHASE2 Recruiting 42
NCT07108309 BCD-236 in Combination With Chemotherapy in Patients With Relapsed and/or Metastatic Triple Negative Breast Cancer PHASE2 Recruiting 124
NCT07220460 Study to Assess the Adverse Events of Oral ABBV-932 in Adult Participants With Depressive Episodes Associated With Bipol... PHASE2 Recruiting 200
NCT06846320 Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in... PHASE2 Recruiting 315
NCT06465420 A Study to Evaluate Safety and Immunogenicity of Haemophilus Influenzae Serotype A Vaccine PHASE1 Active Not Recruiting 30
NCT07543744 A Comparative Study of Pharmacokinetics, Safety, and Immunogenicity of RPH-030 and Vectibix® in Patients With Metastati... PHASE1 Recruiting 180

Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.

More Analysis